Chlamydia trachomatis Antibody Testing in Vaginal Mucosal Material versus Blood Samples of Women Attending a Fertility Clinic and an STI Clinic by van den Broek, Ingrid V F et al.
  
 University of Groningen
Chlamydia trachomatis Antibody Testing in Vaginal Mucosal Material versus Blood Samples
of Women Attending a Fertility Clinic and an STI Clinic
van den Broek, Ingrid V F; Land, Jolande A; van Bergen, Jan E A M; Morré, Servaas A; van
der Sande, Marianne A B
Published in:
Obstetrics and Gynecology International
DOI:
10.1155/2014/601932
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2014
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van den Broek, I. V. F., Land, J. A., van Bergen, J. E. A. M., Morré, S. A., & van der Sande, M. A. B.
(2014). Chlamydia trachomatis Antibody Testing in Vaginal Mucosal Material versus Blood Samples of
Women Attending a Fertility Clinic and an STI Clinic. Obstetrics and Gynecology International, 2014,
[601932]. https://doi.org/10.1155/2014/601932
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Research Article
Chlamydia trachomatis Antibody Testing in Vaginal Mucosal
Material versus Blood Samples of Women Attending a Fertility
Clinic and an STI Clinic
Ingrid V. F. van den Broek,1 Jolande A. Land,2 Jan E. A. M. van Bergen,1,3,4
Servaas A. Morré,5,6 and Marianne A. B. van der Sande1,7
1 Epidemiology & Surveillance Unit, Centre for Infectious Disease Control, National Institute of Public Health and
the Environment (RIVM), P.O. Box 1 (75), 3720 BA Bilthoven, The Netherlands
2Department of Obstetrics and Gynaecology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001,
9700 RB Groningen, The Netherlands
3 STI AIDS Netherlands (SOA AIDS Nederland), P.O. Box 10845, 1001 EV Amsterdam, The Netherlands
4Department of General Practice, AMC-UVA, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands
5 Laboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU University Medical Centre,
De Boelelaan 1105, 1081 HV Amsterdam, The Netherlands
6 Institute of Public Health Genomics, Department of Genetics and Cell Biology, Research Institutes CAPHRI and GROW,
Faculty of Health, Medicine & Life Sciences, University of Maastricht, P.O. Box 616, 6200 MDMaastricht, The Netherlands
7 Julius Centre UMCU, P.O. Box 85500, 3508 GA Utrecht, The Netherlands
Correspondence should be addressed to Ingrid V. F. van den Broek; ingrid.van.den.broek@rivm.nl
Received 15 November 2013; Revised 23 January 2014; Accepted 6 February 2014; Published 13 March 2014
Academic Editor: Deborah A. Wing
Copyright © 2014 Ingrid V. F. van den Broek et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Background. Chlamydia infections often follow an asymptomatic course but may damage the reproductive tract. Chlamydia
antibodies in serum are used as markers for past infections and can relate to tubal pathology and infertility.This “proof of principle”
study aimed to assess whether Chlamydia antibodies are detectable in easier to obtain, noninvasive, vaginal mucosa samples and
relate to current or past infection.Methods.We compared outcomes of Chlamydia IgG and IgA antibody tests in serum and vaginal
mucosal swabs in (a) 77 women attending a fertility clinic, of whom 25 tested positive for serum-IgG and (b) 107 women visiting
an STI centre, including 30 Chlamydia PCR-positive subjects. Results. In the STI clinic, active Chlamydia infections were linked to
serum-IgG and serum-IgA (𝑃 < 0.001) and mucosa-IgA (𝑃 < 0.001), but not mucosa-IgG. In the fertility clinic, mucosa-IgG had
stronger correlations with serum-IgG (𝑃 = 0.02) than mucosa-IgA (𝑃 = 0.06). Women with tubal pathology or Chlamydia history
more commonly had serum-IgG and mucosa-IgA (both 𝑃 < 0.001), whereas this link was weaker for mucosa-IgG (𝑃 = 0.03).
Conclusion. Chlamydia IgG and IgA are detectable in vaginal mucosal material. Serum-IgG had stronger associations with current
or past infections. Mucosa-IgA also showed associations with (past) infection and complications. IgA presence in vaginal mucosa
warrants further epidemiological studies.
1. Introduction
Chlamydia trachomatis is a common sexually transmitted
infection among adolescents. In women, lower genital tract
infections (cervicitis) may ascend to the upper genital tract
and cause pelvic inflammatory disease (PID), potentially
leading to tubal pathology and subsequent infertility [1, 2].
Chlamydia cervicitis and PID often remain asymptomatic
and PID is difficult to define and diagnose [3], which makes
treatment and surveillance of late sequelae difficult. It may
take a decade or more before tubal pathology as a cause
of infertility becomes apparent, and the invasive and costly
surgical procedure of laparoscopy remains the recommended
way of diagnosis [4].
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Various immunological markers have been studied for
their ability to indicate an individual’s history of Chlamydia
infection and increased probability for late complications
[5–8]. In infertile women, the presence of Chlamydia IgG
antibodies in serum is associated with tubal pathology and
lower natural conception rates, even in case of tubal patency
[9]. Elevated levels of anti-Chlamydia antibodies can be
detected in 30–70% of womenwith tubal pathology [5, 10–12]
compared to around 10–20% in the general female population
of reproductive age [13, 14]. In fertility clinics in the Nether-
lands, Chlamydia IgG antibody testing (IgG-CAT) in serum
is used as a screening test for tubal pathology and for selecting
high-risk patients for laparoscopy [15, 16]. A more proximal,
noninvasive biomarker enabling selection of women at high
risk of late complications of Chlamydia infection would be
useful for targeted prevention at the individual level but also
facilitate natural history studies and provide an outcome
marker for screening intervention studies and candidate
vaccine trials [17]. Furthermore, a biomarker in vaginal
material collected by (self-) swab indicating that increased
risk of previous Chlamydia infection, PID or, tubal pathology
could be of high value not only for identifying cases but
also for identifying “controls,” for example, in a population-
based study.The presence of Chlamydia antibodies in vaginal
or cervical samples has not been studied extensively in this
context before, although results of an early study by Brunham
et al. [18] and Agrawal et al. [19] and unpublished data
(Morre´, personal communication) have shown that IgA can
be detected in cervical swab material and in women with
a current Chlamydia infection. It is yet unknown whether
the IgG or IgA CAT assay can be applied in (self-collected)
vaginal swabs of mucosa instead of serum samples. The
advantage would be that this samplingmethod is less invasive
and vaginal samples are available from all women at the time
of a regular Chlamydia (PCR) test.
The further aim of the current “proof of principle” study
was to assess the usefulness of the application of the CAT-
test on mucosal swabs for identification of women who have
or have had an infiltrating Chlamydia infection that could be
the cause of late complications. We hypothesized that local,
mucosal IgG antibodies can persist in the lower genital tract
mucosa for a long time (similar to IgG in serum), while IgA
antibodies may disappear in the course of time, provided that
the infection is cleared. IgA antibodies in serum are assumed
to reflect chronic inflammation and have been shown to be
useful in the serodiagnosis of tubal factor infertility caused
by C. trachomatis [6, 12]. Anti-Chlamydia IgA in serum
has also been linked to another complication of Chlamydia,
that is, LGV [20, 21]. Hence, IgA most likely indicates an
active, on-going, persistent infection, rather than a past,
cleared infection, whichmakes it a potential candidate for the
biomarker we are looking for.
In this study, we compared (A) the correlation between
the outcomes of the serum-IgG CAT and themucosa-CAT in
a group of women at risk for late complications (attending a
fertility clinic) and (B) the correlation between the presence
of Chlamydia DNA (PCR) in vaginal swabs and the outcomes
of the serum-CAT and mucosa-CAT (IgG and IgA), in
women at risk for a current infection (attending an STI
clinic).
2. Methods
2.1. Study Population and Recruitment. We performed a
comparative diagnostic study, in two groups of patients.
(A) Women attending the fertility clinic of the University
Medical Center in Groningen (UMCG) in January and
February 2012: healthy, 20 to 40-year-old women, who had a
serum IgGCAT (CTpELISA,Medac,Wedel,Germany) taken
within the previous year(s) as part of their fertility workup
received a written request to participate. After consent was
given, they received a short questionnaire on past Chlamydia
infections or PID and a test-kit with a vaginal swab for
self-collection. Further relevant data were obtained from the
medical records at a later stage in the clinical investigations.
Recruitment continued until a number of 25 serum-CAT-
positive and 50 serum-CAT-negative women was reached. In
total, 85 agreed to participate and for 79 of them, complete
questionnaire data and samples were obtained (93%), while
results of serological CAT were available for 77 women
(from current or previous clinic visits). Of the 77 women, 52
had serum-CAT-negative results and 25 serum-CAT-positive
results for Chlamydia IgG antibodies, in accordance with
the sampling plan. Mucosa-CAT results (IgG and IgA) were
obtained for all 79 women who returned the swab (see
Figure 1 for details on patient inclusion).The Research Ethics
Board of the UMCG approved this study and all women
provided informed written consent.
(B) Women attending the sexually transmitted infection
(STI) clinic in The Hague between September 2011 and
February 2012: this study population consisted of women of
all ages, who were tested for Chlamydia DNA as part of their
STI consultation and consented to the use of their (anony-
mously stored) remaining sample material from serum and
swab for further STI-related research. During consultation,
standard information on the person’s background and sexual
behaviour and risk factors was collected and entered into an
electronic patient database for STI surveillance. Recruitment
continued until results for 30 PCR-positive and 70 PCR-
negativewomenwere obtained. In total, samplematerial from
117 women was analysed. Results of swabs were available for
115 women and serum results for 102 women; one woman
with serum results only was excluded from analysis. Of the
remaining 116 women, 33 were PCR positive for Chlamydia
and 83 PCR-negative (see Figure 1 for details on numbers
included and tested). The laboratory data for all women were
linkable to anonymized data collected during consultation
in the electronic database by a unique code. Studies using
anonymized patient samples from STI clinics are exempted
from additional ethical review (VUMC Research Ethics
Board for STI Centres in the Netherlands); patients are
informed by poster/leaflet in the clinic that material may be
used for research routinely unless they object.
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Figure 1: Flowchart showing the number of patients selected during recruitment and the number of different CAT tests performed in the
two patient groups.
2.2. Chlamydia Antibodies. The main outcome parameters
were presence of IgG and IgA Chlamydia antibodies in vagi-
nal swabs and in serum. Already available results of serum-
CATwere used for women from the fertility clinic (IgG only).
Serum samples and material collected by vaginal swabs were
analysed with Medac Ct IgG/IgA ELISA test (CT pELISA;
Medac, Wedel, Germany) in the Laboratory of Immuno-
genetics, VU University Amsterdam. Tests were performed
according to manufacturers’ instructions. This Medac test
uses a species-specific synthetic peptide based on the major
outer membrane protein (MOMP) as an antigen, ensuring
minimum cross-reactivity with Chlamydia pneumonia [22,
23]. Performance comparison of the ELISA test to a micro-
immunofluorescence assay found the sensitivity and speci-
ficity of the CAT test to be 71.4 and 97.3, respectively [22].
2.3. Analyses. The qualitative results of serum- and mucosa-
CAT were compared with each other and with PCR results
and proportions with positive IgG/IgA calculated. At the
STI clinic, some test results remained “equivocal” (optical
densities between the values for negativity and positivity),
because the samples could not be submitted to a confirmation
test (1% of serum IgG results, 8% of serum IgA, 11% of swab
IgG, and 7% of swab IgA); these samples were excluded from
further calculations.
In order to evaluate the agreement of the mucosa-CAT
results to the outcomes of PCRand serum-CAT,we calculated
Kappa-values formucosa IgG and IgA versus PCR (in the STI
clinic only) and versus IgG in serum (both for the fertility and
the STI clinic). We searched for potential relations between
IgG or IgA CAT-test outcomes and (determinants of) current
and past Chlamydia infection and sequelae thereof (Chi-
square, univariate and multivariate logistic regression). In
the STI clinic, the question combined history of Chlamydia,
gonorrhoea, or syphilis diagnosis in the past 2 years, but in
this setting and in the age group of heterosexual women,
such a previous STI is most likely to be a Chlamydia episode
[24]. All analyses were performed with IBM SPSS Statistics
(version 19.0).
3. Results
3.1. Population Characteristics. The women in the fertility
clinic had a median age of 32 years (IQR 28–36 yrs.) at the
time of the questionnaire. Fifty-four of 79 (68%) women
reported to have been tested for STI in the past and 13 of
these 54 (24%) reported a history of Chlamydia; one woman
reported a past PID. Clinical data from the women’s medical
records (6 months later) showed that nine women were
diagnosed with tubal pathology and four had experienced
an extrauterine pregnancy, while 12 women had become
pregnant spontaneously and 56women had no tubal damage-
related diagnosis (11 underwent laparoscopy and 27 hysteros-
alpingography, 18 no further diagnostics).
The women at the STI clinic had a median age of 22 years
(IQR 22–25 yrs.). The majority (113/116) had heterosexual
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(a)
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Mucosa-IgA-positive, mucosa IgG negative
Mucosa-IgA-negative, mucosa IgG positive
Mucosa-IgA-negative, mucosa IgG negative
Serum-IgG-negative (n = 56) Serum-IgG-positive (n = 29)
(b)
Mucosa-IgA-positive, mucosa IgG positive
Mucosa-IgA-positive, mucosa IgG negative
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Mucosa-IgA-negative, mucosa IgG negative
Serum-IgA-negative (n = 68) Serum-IgA-positive (n = 10)
PCR-positive (n = 12) PCR-negative (n = 56) PCR-positive (n = 7) PCR-negative (n = 3)
(c)
Figure 2: Proportion of samples with detectable chlamydia specific IgA and IgG in vaginal mucosal samples from women who tested
positive or negative for (a) Chlamydia PCR, (b) Chlamydia IgG in serum, and (c) Chlamydia IgA in serum, at the STI clinic (MHC The
Hague, 2011/2012); connected smaller pie charts below show the same proportions for PCR-positive and PCR-negative samples (indicating
presence/absence of acute infection).
relationships and three were bi-/homosexual; 40 of 116 (34%)
reported to have had one partner in the last 6 months, 28
(24%) had 2 partners, and 47 (41%) had three partners or
more; 106/116 (91%) had a Dutch background and 10 had
non-Dutch background. As a reason for their visit, 24 (21%)
mentioned STI-related complaints and 11 (9.5%)were notified
to get tested by a sex-partner. Among 33 Chlamydia positives,
two had a gonorrhoea infection as well.
3.2. Outcomes of the Chlamydia-Antibody Tests in Serum and
Swab. In the group of women recruited in the STI clinic,
IgG was detected in 36% and IgA in 14% of the sera, while
in the mucosal swabs this was 39% (IgG) and 19% (IgA). In
the selected group of women in the fertility clinic, IgG was
detected in 44% and IgA in 10% of the mucosal swabs; IgG
in serum was reported in 32% of women (selection aimed to
include 25 positives).
3.3. Comparative Analysis Serum-Swab IgG-IgA
(A) Women in the STI Clinic. Of the women with a current,
PCR-confirmed, Chlamydia infection in the STI clinic, the
largemajority (94%) had IgG antibodies and one-third (38%)
had IgA antibodies in the serum, while only 10% of women
without infection had IgG and 6% IgA in the serum. The
correlation between the result of PCR tests was high for
IgG presence in serum (Kappa 0.799, 𝑃 < 0.001) and
modest for IgA (Kappa 0.373, 𝑃 < 0.001). The vaginal swab
material of PCR-positive women tested positive for IgG in
48% of cases and for IgA in 41% of cases, while these values
were 35% and 10% in PCR-negative women (Figure 2(a));
Obstetrics and Gynecology International 5
Table 1: Number and proportion of samples with detectable IgG or IgAChlamydia antibodies per subgroup, determined in serum and vaginal
swab samples from women seen at the STI clinic and at the fertility clinic.
Serum-IgA % Serum-IgG % Swab-IgA % Swab-IgG %
𝑁pos 𝑁total 𝑁pos 𝑁total 𝑁pos 𝑁total 𝑁pos 𝑁total
STI clinic 116 13 93 (14%) 36 100 (36%) 20 107 (19%) 40 102 (39%)
PCR
+ 33 9 24 (38%) 29 31 (94%) 12 29 (41%) 15 31 (48%)
− 83 4 69 (6%) 7 69 (10%) 8 78 (10%) 25 71 (35%)
Ct history
+ 11 1 11 (9%) 8 11 (73%) 2 8 (25%) 2 10 (20%)
− 115 12 81 (15%) 28 88 (32%) 18 98 (18%) 38 92 (41%)
Symptoms
+ 24 2 17 (12%) 11 20 (55%) 4 22 (18%) 6 19 (32%)
− 116 11 76 (14%) 25 80 (31%) 16 85 (19%) 34 83 (41%)
Condom use
+ 34 3 28 (11%) 8 31 (26%) 6 34 (18%) 8 21 (38%)
− 74 9 59 (15%) 27 62 (44%) 14 65 (22%) 31 68 (46%)
Partners < 6 months
0 or 1 41 0 31 (0%) 8 32 (25%) 4 38 (11%) 12 34 (35%)
2 28 5 28 (18%) 8 28 (29%) 6 24 (25%) 10 27 (37%)
3 or more 47 8 34 (24%) 20 40 (50%) 10 45 (22%) 18 41 (44%)
ethnicities
Dutch 106 11 84 (13%) 32 92 (35%) 14 97 (14%) 33 92 (36%)
non-Dutch 10 2 9 (22%) 4 8 (50%) 6 10 (60%) 7 10 (70%)
Fertility clinic 77 n.a. 25 77 (32%) 8 77 (10%) 34 77 (44%)
Tubal pathology
+ 9 8 9 (89%) 4 9 (44%) 5 9 (56%)
− 70 17 68 (25%) 4 64 (6%) 29 68 (43%)
Ct history
+ 21 17 21 (81%) 7 21 (33%) 14 21 (67%)
− 56 8 56 (14%) 1 56 (2%) 20 56 (36%)
Percentages in bold indicate significant differences in proportion positive for that determinant.
here IgA-presence was a better “marker” for PCR positivity
than IgG presence (Kappa IgA 0.345, 𝑃 < 0.001, and IgG
0.122, 𝑃 = 0.21). Comparing the results of serum-CAT and
mucosa-CAT (Figure 2(b)) showed that serum-IgG positivity
had similar associations with mucosal antibodies as PCR
positivity, with Kappa values of 0.336 for IgA (𝑃 = 0.001) and
0.130 (𝑃 = 0.2) for IgG.
Women who tested serum-IgA-positive (𝑛 = 10) often
also had IgA antibodies in the swab (6/10); most serum-IgA-
negative women also had no IgA in the swab (64/74; 86%,
Kappa 0.37, 𝑃 < 0.001). The association between serum-
IgA and swab IgA was most visible in PCR-negative women
(Figure 2(c)).There was no association between IgA in serum
and IgG in swabs (Kappa 0.12, 𝑃 = 0.18).
Women with a history of STI (𝑛 = 11) had a higher
chance to have detectable serum-IgG than women with no
prior STI history (73% versus 32%, 𝑃 = 0.022), but their
chance to have a mucosa-IgG was lower (20% versus 41%,
n.s. 𝑃 = 0.17; see Table 1). IgA presence (serum or swab)
was not correlated to STI history. Other factors influencing
the outcomes of the antibody tests were presence of physical
symptoms, condom use, number of partners in the last 6
months, and ethnicity. Women who came to the STI clinic
with physical complaints (𝑛 = 20) had a higher chance to have
a positive IgG in serum than women who had no complaints
(55% versus 31%, 𝑃 = 0.045). Similar differences were seen
for women who reported not to have used a condom at the
last sexual contact (𝑛 = 31) compared to those who did (26%
versus 44%, 𝑃 = 0.044; see Table 1). No relation with IgA in
serum or mucosa was found. The number of partners in the
last 6 months (in three categories: 0 or 1, 2, and 3 or more)
was a determinant for serum-IgA (𝑃 = 0.019) and borderline
for serum-IgG (𝑃 = 0.06), but not for mucosa-IgG or -IgA
presence. Women with a non-Dutch background (𝑛 = 10),
mucosal CAT results were more often positive for IgG (70%)
and IgA (60%) than among Dutch women (36% and 14%,
𝑃 = 0.04 and 𝑃 = 0.003), whereas there was no significant
difference in the proportion serum-CAT positives.
(B)Women in the Fertility Clinic.Amongwomenwith serum-
IgG, 64% also had IgG antibodies in the vaginal mucosa,
while 35% of the seronegative women tested positive for
mucosa-IgG (Figure 2). The Kappa value indicated a modest
rate of agreement between systemic and local IgG tests
(Kappa 0.27, 𝑃 = 0.015). Mucosa-IgA was found in 20% of
thewomenwith serum-IgG and in 6%of the serum-negatives
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Table 2: Comparison of the sensitivity, specificity, and agreement between test results of different antibodies in serum and swab with active
or past Chlamydia infection or complications thereof, in fertility clinic and STI clinic.
Sensitivity Specificity Kappa-value
Fertility clinic
Probable past Ct infection#, PID, or tubal pathology reported
Serum-IgG 79% 89% 0.67 (𝑃 < 0.001)
Swab-IgG 63% 64% 0.23 (𝑃 = 0.03)
Swab-IgA 29% 98% 0.34 (𝑃 < 0.001)
Tubal pathology
Serum-IgG 89% 75% 0.36 (𝑃 < 0.001)
Swab-IgG 56% 57% 0.06 (𝑃 = 0.47)
Swab-IgA 56% 94% 0.41 (𝑃 < 0.001)
STI clinic
Active infection∗/probable past Ct infection#
Serum-IgG 87% 95% 0.83 (𝑃 < 0.001)
Serum-IgA 32% 95% 0.32 (𝑃 < 0.001)
Swab-IgG 43% 63% 0.06 (𝑃 = 0.53)
Swab-IgA 38% 90% 0.32 (𝑃 < 0.001)
∗Active infection: PCR positive at STI clinic.
#Probable past Chlamydia infection. #: history of STI at STI clinic or reported Chlamydia infection in the past or complications related to chlamydia (PID,
tubal pathology) in fertility clinic.
Mucosa-IgA-positive, mucosa IgG positive
Mucosa-IgA-positive, mucosa IgG negative
Mucosa-IgA-negative, mucosa IgG positive
Mucosa-IgA-negative, mucosa IgG negative
Serum-IgG-negative (n = 52) Serum-IgG-positive (n = 25)
Figure 3: Proportion of samples with detectable chlamydia specific
IgA and IgG in vaginal mucosal samples from women who tested
positive or negative for Chlamydia IgG in serum, at the fertility clinic
(University Medical Centre Groningen, 2012).
(Figure 3), resulting in a lower rate of agreement (Kappa 0.17;
𝑃 = 0.055).
Women diagnosed with a reported tubal pathology diag-
nosis (𝑁 = 9) more often tested positive on serum-IgG (89%)
than women without tubal pathology (25%, 𝑃 < 0.001) and
more often for mucosa-IgA (44% versus 6%, 𝑃 = 0.005),
but not for mucosa-IgG (56% versus 43%). Similarly, women
with a history of Chlamydia infection (self-reported or noted
in medical records; 𝑛 = 21) more often had serum-IgG
and mucosa-IgA and -IgG than those without such a history
(serum-IgG: 81 versus 14%, 𝑃 < 0.001; mucosa-IgA: 33 versus
1.7%, 𝑃 < 0.001; mucosa-IgG: 67 versus 36%, 𝑃 = 0.02).
3.4. Results from the Two Study Cohorts Together. In samples
from women in the STI clinic, Chlamydia infections (deter-
mined by PCR) were linked to both serum-IgG (Figure 2)
and serum-IgA and to mucosa-IgA, but not to mucosa-IgG.
In women in the fertility clinic, IgG in serum was found in
most women with tubal pathology and in women reporting a
history of Chlamydia. We also found that women with tubal
pathology or Chlamydia history more often hadmucosal IgA
than women with neither of these, whereas this difference
was not seen for mucosal IgG. In the STI clinic, mucosa-IgA
correlated with serum-IgG in serum. In the group of women
recruited at the fertility clinic, mucosa-IgG had a stronger
correlation with serum-IgG than with mucosa-IgA.
Altogether, IgG in serum was the best predictor for a
current or probable past Chlamydia infection (combining
PCR-confirmed current infection with a history of STI) in
the STI clinic and also the best predictor for “Chlamydia
and related complications” (combining Chlamydia history,
PID, and tubal pathology) in the fertility clinic. IgA in swabs
showed high specificity for tubal pathology in the fertility
clinic and Kappa values were consistently higher for IgA than
IgG in swab (see Table 2).
4. Discussion
Chlamydia antibody testing can detect local IgG and IgA
in vaginal mucosal swab material from women with a
currentChlamydia infection or probable exposure in the past.
The correlations between local anti-Chlamydia antibodies
and systemic antibodies or (past) Chlamydia infection were
however not unambiguous and warrant further prospective
studies. IgG antibodies in serum were the best predictor of a
current or potential past Chlamydia infection, in both groups
under study: women at the STI clinic and in the fertility clinic.
Serum-IgG results were not exchangeable with the results
of antibody tests in vaginal mucosa in a straightforward
way; however,mucosa-IgA showed amodest associationwith
(past) Chlamydia infection but a stronger association, also
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compared to serum-IgG, with tubal pathology as a poten-
tial long-term complication thereof. Combining results on
systemic andmucosal immunological responses seems prom-
ising to getmore insights into the pathogenesis of Chlamydia.
It is known that up to 80% of the Chlamydia infections
in women are asymptomatic [25], and therefore infections
are often not detected and treated. Most infected women
seem to have an adequate local immune response to clear the
infection within months or years thereafter (45% after one
year [26], 94% at 4 years of follow-up [27]), but a small pro-
portion of infectedwomenwill have a long-lastingChlamydia
infection. A persistent (silent) Chlamydia infection [28, 29]
can cause a chronic low-grade immune response, which
might induce destruction of tubal epithelial cells and cause
tubal pathology [30]. Systemic antibodies correlate to (past)
Chlamydia infections and related complications [5–12]. Little
is known about the presence of local Chlamydia antibodies
in the cervicovaginal mucosa. The dominant Chlamydia
antibody in cervicovaginal fluid is IgG rather than IgA [31].
In women with a current Chlamydia infection, presence of
combined Ct IgMAG antibodies was recorded in 83% and
IgA in 38% [18]; interestingly IgA showed a clear (inverse)
correlation with the number of bacteria detected in the
cervical secretions tested. Another study reported a 43% IgG
and 42% IgA prevalence in cervical material of women with
a current infection whereas both prevalences were 7% in
women with no current infection or indication of a past
infection (no systemic IgG) [19]. These authors also reported
that the mucosal antibody prevalence was higher in women
with a primary Chlamydia infection than women with a
recurrent infection, and this difference was more obvious for
IgG (78% in primary and 23% in recurrent infections) than
for IgA (52% versus 37%). In our study,mucosal IgA appeared
to have a stronger predictive value than IgG. IgA presence
in vaginal mucosa might indicate an ongoing Chlamydia
infection or chronic low-grade immune response in the upper
genital tract, in women who have negative PCR results of
the lower genital tract. To investigate this further, a more
longitudinal study on the outcome of IgA positivity in the
vaginal mucosa in (a cohort of) women with a known past
or recent Chlamydia infection would be required.
Our study was unique in exploring the added value of
using mucosal (self) swabs to identify markers for adverse
outcomes of Ct infections. On the other hand, as this
was a small exploratory study, only preliminary conclusions
can be drawn; further research and test validation are
recommended. Due to the small and selective sample, the
estimation of (adjusted) risk factors (as shown in Table 1)may
have been biased. We saw a few women with negative serum-
IgG/IgA but positive mucosal IgG/IgA test results or vice
versa. We think that these are true “discrepancies” between
mucosal and serological samples, indicating that only a local
response to the Chlamydia infection was evoked, but in
further studies, CAT tests for mucosal material should be
validated to confirm that specificity for local antibodies in the
mucosa is as good as for serological antibodies.There may be
different subtypes of antibodies in serum and in other body
fluids (dimeric, “secretory IgG/IgA”, versus serum IgG/IgA or
subclasses such as IgG1, IgG2, etc.). There is limited informa-
tion available regarding IgG subtype and class responses after
genital Chlamydia trachomatis infections [32]. The goat-anti-
human Chlamydia antibodies of the conjugate in the Medac
pELISA are considered to detect different subtypes as well
as the dimeric form (personal communication with Dr. K.
Dreesbach, Medac Germany). Furthermore, cervical IgA and
IgG levels may fluctuate during different phases of the men-
strual cycle [33, 34]. Although it is not known if this also holds
for Chlamydia antibodies and to what extent, this may have
influenced themucosal CAT results of some of the patients in
our study (we had no information on the menstrual cycle of
the women in study). The representativeness of the patients
in our study was limited due to the predetermined selection
of one-third per patient group with positive and two-thirds
with negative results for the CAT-test (in the fertility clinic)
and the PCR (in the STI clinic). The proportion of serum-
IgG-positive samples among PCR-positives was higher (94%)
than what was previously reported (30–70% [5, 10–12, 35]).
Our data suggest that local IgA antibodies might have a
stronger discriminative value than local IgG, as IgA presence
in the vaginal mucosa was associated with tubal pathology
and history of Chlamydia infection in women in the fertility
clinic and it correlated to current Chlamydia infection and
to the presence of IgG in serum in the group of women in
the STI clinic. Provided that the mucosal CAT test has a
high specificity, larger population-based studies and further
prospective cohort studies are needed to assess to what
extent and when IgA in vaginal (self-)swabs could be of
value as a biomarker, on its own or in combination with
other immunological host-related markers, indicating which
women have a higher chance to develop late sequelae from
Chlamydia infections.
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